Publications

Protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré Syndrome
PubMed

Regional variation of Guillain-Barré syndrome
PubMed
Key findings: GBS incidence increases during age. Predominance is found in males and there is geographical variation in clinical variants, NCS subtype, preceding infections and outcome.

Guillain–Barré syndrome in Denmark: a population-based study on epidemiology, diagnosis and clinical severity
PubMed

Cerebrospinal Fluid Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome
PubMed
Key findings: albumino-cytological dissociationis found in 70% of the patients. CSF can be helpful to support the diagnosis, although a normal CSF protein level does not exclude the diagnosis. An increased cell count is rare in GBS patients.

Current treatment practice of Guillain-Barré syndrome
PubMed
Key findings: Variability is found in administered treatment across regions. Patients with mild and variant forms of GBS, or with treatment-related fluctuations and treatment failures, are frequently treated, even in absence of trial data to support this choice.

Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study
PubMed
Key findings: At baseline and week 1, patients receiving two IVIg courses were more disabled than those receiving one course. Despite the limitations, there was no prove for a second IVIg course in GBS with poor prognosis.

Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study
PubMed
Key findings: IVIg is not associated with better GBS-DS at week 4 of week 26. After 1 year, 40% of the patients had residual symptoms. Despite the limitations, there was no prove for IVIg in mild GBS patients.

Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study
PubMed
Key findings: SARS-CoV-2 may rarely precede GBS. There was no increase in recruitment rate IGOS during the first wave of the pandemic. 8/49 patients had confirmed, 3 had probable SARS-CoV-2. Those patients had uniform features, similar to other post-viral GBS patients.

Antecedent infections in Guillain-Barré syndrome in endemic areas of arbovirus transmission: A multinational case-control study
PubMed
Key findings: This study was conducted outside the time period of the Zika virus pandemic. There were no differences in preceding arbovirus infections between cases and controls. Arbovirus infections do occur in GBS outside epidemic viral transmission, but larger studies are necessary to establish a causal association.

An International Perspective on Preceding Infections in Guillain-Barré Syndrome: The IGOS 1000-Cohort
PubMed
Key findings: 30% of the patients had positive serology for Campylobacter bacteria, 4% for Cytomegalo virus, 1% for Epstein-Barr virus, 3% for Hepatitis E virus and 10% for Mycoplasma bacteria. 6% of patients had positive serology for multiple recent infections and >50% had no recent infection. The distribution of infections was similar across regions.

Large-scale profiling of antibody reactivity to glycolipids in patients with Guillain-Barré syndrome
PubMed
Key findings: Most patients with Guillain‑Barré syndrome have antibodies against glycolipids or glycolipid complexes, that antibodies to glycolipid complexes outperform single ganglioside antibodies in distinguishing clinical variants (including motor GBS and Miller Fisher syndrome), and that distinct antibody reactivity patterns are associated with geography, antecedent infection, electrophysiology, disease severity, and outcome, supporting their added diagnostic and pathophysiological relevance.

Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values
PubMed
Key findings: There is a need for standardization of Edx in future multinational GBS studies, as there is a marked variability between IGOS centers in motor and sensory reference values (although only a few outliers accounted for this). This variability is likely to be present in other neuromuscular disorders and centers as well.

Electrodiagnostic subtyping in Guillain-Barré syndrome: use of criteria in practice based on a survey study in IGOS
PubMed
Key findings: The minimum number of motor nerves to study in a suspicious GBS patient varied. A lot of variability is found in the use of various published criteria sets for subtyping GBS, which potentially lowers the reproducibility of GBS subtyping.

Electrodiagnostic subtyping in Guillain-Barré syndrome patients in the International Guillain-Barré Outcome Study
PubMed
Key findings: Electrodiagnosis subtyping in GBS is dependent on the criterion set utilized and reappraisal is warranted.

Dynamics of Nerve Conduction Studies in Patients With Guillain-Barré Syndrome
PubMed
Key findings: Nerve conduction study findings in Guillain–Barré syndrome are highly dynamic over time, with frequent changes in electrodiagnostic subtypes on serial testing, indicating that early NCS mainly support the clinical diagnosis while electrodiagnostic subtyping has limited additional value.

International Validation of the Erasmus Guillain-Barré Syndrome Respiratory Insufficiency Score
PubMed
Key findings: Validation of the Erasmus Guillain–Barré Syndrome Respiratory Insufficiency Score, demonstrating good discrimination for predicting the need for mechanical ventilation across diverse GBS populations and showing that recalibration improves regional accuracy, particularly in Europe and North America.

Validation and adjustment of modified Erasmus GBS outcome score in Bangladesh
PubMed
Key findings: Validation of the modified Erasmus Guillain–Barré Syndrome Outcome Score (mEGOS) in Bangladeshi patients, showing moderate-to-good discrimination for predicting inability to walk at 4 and 26 weeks and demonstrating that recalibration improves accuracy, making it useful for identifying high‑risk patients and guiding resource allocation in low‑resource settings.

Predicting Outcome in Guillain-Barré Syndrome: International Validation of the Modified Erasmus GBS Outcome Score
PubMed
Key findings: Validation of the modified Erasmus Guillain–Barré Syndrome Outcome Score (mEGOS), showing that it reliably predicts inability to walk independently at 4 and 26 weeks across regions, with recalibration improving accuracy and confirming age and severity of weakness as the strongest predictors of poor outcome.

Modified Erasmus GBS Respiratory Insufficiency Score: a simplified clinical tool to predict the risk of mechanical ventilation in Guillain-Barré syndrome
PubMed
Key findings: Development and validation of the modified Erasmus Guillain‑Barré Syndrome Respiratory Insufficiency Score (mEGRIS), a simpler clinical tool based on early onset of weakness, bulbar involvement, and neck and hip flexion weakness, which accurately predicts the risk of mechanical ventilation across regions with similar performance to the original score while requiring fewer variables.

Measurement properties of the Inflammatory Rasch-built Overall Disability Scale (I-RODS) in patients with Guillain-Barré syndrome
PubMed
Key findings: The I‑RODS demonstrates excellent internal consistency and acceptable construct validity in patients with Guillain‑Barré syndrome, but has suboptimal unidimensionality, item misfit, and geographic differential item functioning, indicating that the current scale could be improved or that alternative patient‑reported outcome measures may be needed.